| Programmed cell death 10 can be used as a potential biomarker for ankylosing spondylitis diagnosis and treatment. | Programmed cell death 10 can be used as a potential biomarker for ankylosing spondylitis diagnosis and treatment.
Ni WJ, Leng XM. | 03/13/2024 |
| Comprehensive CCM3 Mutational Analysis in Two Patients with Syndromic Cerebral Cavernous Malformation. | Comprehensive CCM3 Mutational Analysis in Two Patients with Syndromic Cerebral Cavernous Malformation.
da Fontoura Galvão G, da Silva EV, Trefilio LM, Alves-Leon SV, Fontes-Dantas FL, de Souza JM. | 02/26/2024 |
| Knockdown of CCM3 promotes angiogenesis through activation and nuclear translocation of YAP/TAZ. | Knockdown of CCM3 promotes angiogenesis through activation and nuclear translocation of YAP/TAZ.
Tang L, Zhou M, Xu Y, Peng B, Gao Y, Mo Y. | 02/23/2024 |
| PDCD10 promotes proliferation, migration, and invasion of osteosarcoma by inhibiting apoptosis and activating EMT pathway. | PDCD10 promotes proliferation, migration, and invasion of osteosarcoma by inhibiting apoptosis and activating EMT pathway.
Xu K, Fei W, Huo Z, Wang S, Li Y, Yang G, Hong Y., Free PMC Article | 02/4/2023 |
| PDCD10 promotes the aggressive behaviors of pituitary adenomas by up-regulating CXCR2 and activating downstream AKT/ERK signaling. | PDCD10 promotes the aggressive behaviors of pituitary adenomas by up-regulating CXCR2 and activating downstream AKT/ERK signaling.
Liu J, Wang J, Tian W, Xu Y, Li R, Zhao K, You C, Zhu Y, Bartsch JW, Niu H, Zhang H, Shu K, Lei T., Free PMC Article | 08/27/2022 |
| Improving clinical interpretation of five KRIT1 and PDCD10 intronic variants. | Improving clinical interpretation of five KRIT1 and PDCD10 intronic variants.
Fusco C, Nardella G, Petracca A, Ronchi D, Paciello N, Di Giacomo M, Gambardella S, Lanfranconi S, Zampatti S, D'Agruma L, Micale L, Castori M. | 02/19/2022 |
| Programmed cell death 10 promotes metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma via PP2Ac-mediated YAP activation. | Programmed cell death 10 promotes metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma via PP2Ac-mediated YAP activation.
Sun B, Zhong FJ, Xu C, Li YM, Zhao YR, Cao MM, Yang LY., Free PMC Article | 01/29/2022 |
| CircSMARCA5 Facilitates the Progression of Prostate Cancer Through miR-432/PDCD10 Axis. | CircSMARCA5 Facilitates the Progression of Prostate Cancer Through miR-432/PDCD10 Axis.
Dong C, Fan B, Ren Z, Liu B, Wang Y. | 10/9/2021 |
| CCM3 is a gatekeeper in focal adhesions regulating mechanotransduction and YAP/TAZ signalling. | CCM3 is a gatekeeper in focal adhesions regulating mechanotransduction and YAP/TAZ signalling.
Wang S, Englund E, Kjellman P, Li Z, Ahnlide JK, Rodriguez-Cupello C, Saggioro M, Kanzaki R, Pietras K, Lindgren D, Axelson H, Prinz CN, Swaminathan V, Madsen CD. | 09/25/2021 |
| Programmed Cell Death 10 Mediated CXCL2-CXCR2 Signaling in Regulating Tumor-Associated Microglia/Macrophages Recruitment in Glioblastoma. | Programmed Cell Death 10 Mediated CXCL2-CXCR2 Signaling in Regulating Tumor-Associated Microglia/Macrophages Recruitment in Glioblastoma.
Zhang Q, Wang J, Yao X, Wu S, Tian W, Gan C, Wan X, You C, Hu F, Zhang S, Zhang H, Zhao K, Shu K, Lei T., Free PMC Article | 09/25/2021 |
| Down-regulated miR-495 can target programmed cell death 10 in ankylosing spondylitis. | Down-regulated miR-495 can target programmed cell death 10 in ankylosing spondylitis.
Ni WJ, Leng XM., Free PMC Article | 09/11/2021 |
| Non-canonical signaling pathway of SNAI2 induces EMT in ovarian cancer cells by suppressing miR-222-3p transcription and upregulating PDCD10. | Non-canonical signaling pathway of SNAI2 induces EMT in ovarian cancer cells by suppressing miR-222-3p transcription and upregulating PDCD10.
Fan L, Lei H, Zhang S, Peng Y, Fu C, Shu G, Yin G., Free PMC Article | 08/7/2021 |
| Emerging roles of CCM genes during tumorigenesis with potential application as novel biomarkers across major types of cancers. | Emerging roles of CCM genes during tumorigenesis with potential application as novel biomarkers across major types of cancers.
Abou-Fadel J, Qu Y, Gonzalez EM, Smith M, Zhang J., Free PMC Article | 10/24/2020 |
| Distinct cellular roles for PDCD10 define a gut-brain axis in cerebral cavernous malformation. | Distinct cellular roles for PDCD10 define a gut-brain axis in cerebral cavernous malformation.
Tang AT, Sullivan KR, Hong CC, Goddard LM, Mahadevan A, Ren A, Pardo H, Peiper A, Griffin E, Tanes C, Mattei LM, Yang J, Li L, Mericko-Ishizuka P, Shen L, Hobson N, Girard R, Lightle R, Moore T, Shenkar R, Polster SP, Rödel CJ, Li N, Zhu Q, Whitehead KJ, Zheng X, Akers A, Morrison L, Kim H, Bittinger K, Lengner CJ, Schwaninger M, Velcich A, Augenlicht L, Abdelilah-Seyfried S, Min W, Marchuk DA, Awad IA, Kahn ML., Free PMC Article | 09/12/2020 |
| showed a population-specific mutational and clinical spectrum of multiple CCMs. These findings broaden the mutational spectrum in CCMs and highlight the importance of screening for deletions in the CCM genes in patients with multiple CCMs | Phenotypic variability in xeroderma pigmentosum group G: An uncommon case with severe prenatal-onset Cockayne syndrome features.
Ricotti R, Nardo T, Striano P, Stefanini M, Orioli D, Botta E. | 11/2/2019 |
| Study identified a novel large deletion in PDCD10 gene in patients with cerebral cavernous malformation (CCM) and explored its cellular effect which associated with significant reduction of interactions between KRIT1 and CCM2, and impaired autophagy process. | A single-center study on 140 patients with cerebral cavernous malformations: 28 new pathogenic variants and functional characterization of a PDCD10 large deletion.
Nardella G, Visci G, Guarnieri V, Castellana S, Biagini T, Bisceglia L, Palumbo O, Trivisano M, Vaira C, Scerrati M, Debrasi D, D'Angelo V, Carella M, Merla G, Mazza T, Castori M, D'Agruma L, Fusco C. | 10/12/2019 |
| Loss of programmed cell death 10 activates tumor cells and leads to temozolomide-resistance in glioblastoma, suggesting PDCD10 as a potential target for glioblastoma therapy. | Loss of programmed cell death 10 activates tumor cells and leads to temozolomide-resistance in glioblastoma.
Nickel AC, Wan XY, Saban DV, Weng YL, Zhang S, Keyvani K, Sure U, Zhu Y. | 04/20/2019 |
| We showed that overexpression of PDCD10 significantly inhibited miR-103-induced inhibition of cell proliferation, increased apoptosis, and decreased invasion and migration in A549 cells. | miR-103 Functions as a Tumor Suppressor by Directly Targeting Programmed Cell Death 10 in NSCLC.
Yang D, Wang JJ, Li JS, Xu QY., Free PMC Article | 12/29/2018 |
| Data show that PDCD10 expression levels are high in bladder cancer (BC) tissues and seems to correlate with worse prognosis. PDCD10 is directly modulated by miR26a/miR26b as a target in BC cells. PDCD10 promotes BC cell proliferation in vitro and growth and progression of BC in vivo. | miRNA‑26a‑5p and miR‑26b‑5p inhibit the proliferation of bladder cancer cells by regulating PDCD10.
Wu K, Mu XY, Jiang JT, Tan MY, Wang RJ, Zhou WJ, Wang X, He YY, Li MQ, Liu ZH. | 12/22/2018 |
| Over-expression of PDCD10 in HeLa cells increased the resistance to doxorubicin. | Dual function of programmed cell death 10 (PDCD10) in drug resistance.
Urfali-Mamatoglu C, Kazan HH, Gündüz U. | 09/29/2018 |
| The identified endothelial signalling pathway of CCM3-DLL4/Notch-EphB4-Erk1/2 may provide an insight into mechanism of CCM3-ablation-mediated angiogenesis. | EphB4 forward signalling mediates angiogenesis caused by CCM3/PDCD10-ablation.
You C, Zhao K, Dammann P, Keyvani K, Kreitschmann-Andermahr I, Sure U, Zhu Y., Free PMC Article | 06/2/2018 |
| Case-control study to investigate the possible association of others polymorphisms (c.485+65 C/G, c.989+63 C/G, c.1980 A/G in CCM1 gene, c.472+127 C/T in CCM2 and c.150 G/A in CCM3) with cerebral cavernous malformations. The five polymorphisms were characterized in 64 sporadic patients and in 90 healthy controls by ASO-PCR. Results suggest that some polymorphisms in CCM genes could play an important role in the disease. | Relevance of CCM gene polymorphisms for clinical management of sporadic cerebral cavernous malformations.
Rinaldi C, Bramanti P, Scimone C, Donato L, Alafaci C, D'Angelo R, Sidoti A. | 05/12/2018 |
| CCM3 restrains ANGPT2 release from endothelial cells and maintains endothelial junctions. CCM3 depletion leads to increased ANGPT2 release. | Endothelial exocytosis of angiopoietin-2 resulting from CCM3 deficiency contributes to cerebral cavernous malformation.
Jenny Zhou H, Qin L, Zhang H, Tang W, Ji W, He Y, Liang X, Wang Z, Yuan Q, Vortmeyer A, Toomre D, Fuh G, Yan M, Kluger MS, Wu D, Min W., Free PMC Article | 08/12/2017 |
| Data indicated that rs9853967 and rs11714980 polymorphisms in CCM3 and SERPINI1respectively could be associated with a protective role in cerebral cavernous malformations disease. | CCM3/SERPINI1 bidirectional promoter variants in patients with cerebral cavernous malformations: a molecular and functional study.
Scimone C, Bramanti P, Ruggeri A, Donato L, Alafaci C, Crisafulli C, Mucciardi M, Rinaldi C, Sidoti A, D'Angelo R., Free PMC Article | 05/6/2017 |
| Inhibition of Notch and activation of VEGF/p38 signaling were involved in miR-425-5p/CCM3 mediated inhibition of angiogenesis by sodium arsenite. | Arsenic-induced anti-angiogenesis via miR-425-5p-regulated CCM3.
Gao Y, Yin Y, Xing X, Zhao Z, Lu Y, Sun Y, Zhuang Z, Wang M, Ji W, He Y. | 02/4/2017 |